Efficacy and Safety of Bempedoic Acid Added to Maximally Tolerated Statins in Patients With Hypercholesterolemia and High Cardiovascular Risk - CLEAR Wisdom
Contribution To Literature:
The CLEAR Wisdom trial showed that bempedoic acid is safe and effective in reducing LDL-C compared with placebo among patients with ASCVD or heterogeneous FH on maximum-tolerated statin therapy.
The goal of the trial was to compare the safety and efficacy of bempedoic acid compared with placebo among patients already on intensive or maximum-tolerated statin therapy.
Patients were randomized in a 2:1 fashion to either bempedoic acid 180 mg or placebo once daily for 52 weeks. All patients were on maximal tolerated statin and other lipid-lowering therapy.
- Total number screened: 2,300
- Total number of enrollees: 779
- Duration of follow-up: 52 weeks
- Mean patient age: 64.5 years
- Percentage female: 36%
- Percentage with diabetes: 30%
- Pre-existing atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (FH)
- Baseline low-density lipoprotein cholesterol (LDL-C) ≥100 mg/dl (2.6 mmol/L) at screening and ≥70 mg/dl (1.8 mmol/L) following placebo run-in while receiving maximally tolerated statins
Other salient features/characteristics:
- ASCVD alone: 94%
- Baseline LDL-C: 120 mg/dl; non-high-density lipoprotein (non-HDL): 153 mg/dl
- High-intensity statin: 53%, moderate-intensity statin: 31%
The primary outcome, change in LDL-C from baseline for bempedoic acid compared with placebo, was -15.1% vs. 2.4%, p < 0.001.
- Observed LDL-C at 4 weeks for bempedoic acid vs. placebo: 97.6 vs. 122.8 mg/dl; at 52 weeks: 99.6 vs. 116.9 mg/dl
- Change in apolipoprotein B from baseline at week 12: -9.3% vs. 3.7%, p < 0.001
- Change in high-sensitivity C-reactive protein from baseline at week 12: -18.7% vs. -9.4%, p = 0.039
- Serious side effects: 20.3% vs. 18.7%, p = 0.63
- Five-point major adverse cardiac events: 6.1% vs. 8.2%, p > 0.05
- Nonfatal myocardial infarction: 1.1% vs. 3.5%
The results of this trial indicate that bempedoic acid is safe and effective in reducing LDL-C compared with placebo among patients with ASCVD or heterogeneous FH on maximum-tolerated statin therapy. No difference was noted for clinical outcomes, although the trial was not powered for this. These are encouraging data, but outcomes data are needed prior to recommending this agent to patients. Several agents have impacted on surrogate markers (such as niacin for HDL), which were then found to have a neutral or in some cases, a harmful effect on clinical outcomes. Also, future studies comparing bempedoic acid to other nonstatin lipid-lowering agents such as ezetimibe and PCSK9 inhibitors would be helpful for patient management.
Presented by Dr. Anne C. Goldberg at the American College of Cardiology Annual Scientific Session (ACC 2019), New Orleans, LA, March 18, 2019.
Keywords: ACC19, ACC Annual Scientific Session, Apolipoproteins B, Biological Markers, Cholesterol, HDL, Cholesterol, LDL, C-Reactive Protein, Dicarboxylic Acids, Dyslipidemias, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia, Hyperlipoproteinemia Type II, Myocardial Infarction, Primary Prevention
< Back to Listings